Current treatment status-Undergoing active treatment-Partial response Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment-Partial response Posts on Medivizor

Evaluating the long-term effectiveness and safety of daratumumab plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma.

Evaluating the long-term effectiveness and safety of daratumumab plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma.

Posted by on Aug 27, 2023 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the long-term effectiveness and safety of daratumumab (D; Darzalex) plus bortezomib (V; Velcade) and dexamethasone (d; Decadron) (D-Vd) regimen in patients with relapsed or refractory (r/r) multiple myeloma (MM). The data showed that the D-Vd regimen significantly increased the overall survival in these patients. Some...

Read More

Evaluating the effectiveness and safety of sacituzumab govitecan versus chemotherapy in patients with HR+, HER2– metastatic breast cancer.

Evaluating the effectiveness and safety of sacituzumab govitecan versus chemotherapy in patients with HR+, HER2– metastatic breast cancer.

Posted by on Apr 23, 2023 in Breast cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of sacituzumab govitecan (Trodelvy; SG) compared to chemotherapy in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer (BC). The data showed that SG significantly improved survival without cancer progression compared to chemotherapy in these...

Read More

Evaluating the effectiveness of abemaciclib alone or in combination with tamoxifen in patients with HR+, HER2– metastatic breast cancer resistant to hormone therapy.

Evaluating the effectiveness of abemaciclib alone or in combination with tamoxifen in patients with HR+, HER2– metastatic breast cancer resistant to hormone therapy.

Posted by on Jan 8, 2023 in Breast cancer | 0 comments

In a nutshell This study evaluated the effectiveness of abemaciclib (Verzenio) alone or in combination with tamoxifen (Nolvadex) in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer (BC) resistant to hormone therapy. The data showed that abemaciclib in combination with tamoxifen was more effective in improving...

Read More

Ibrutinib and venetoclax treatment for patients with relapsed or refractory chronic lymphocytic leukemia according to minimal residual disease status.

Ibrutinib and venetoclax treatment for patients with relapsed or refractory chronic lymphocytic leukemia according to minimal residual disease status.

Posted by on Dec 4, 2022 in Leukemia | 0 comments

In a nutshell This study investigated the effectiveness and safety of time-limited treatment with ibrutinib (Imbruvica) plus venetoclax (Venclexta) for patients with relapsed or refractory (r/r) chronic lymphocytic leukemia (CLL) by using minimal residual disease (MRD) guidance. The data showed that time-limited treatment with ibrutinib plus venetoclax...

Read More

Evaluating the safety and effectiveness of tebentafusp in previously treated patients with advanced uveal melanoma

Evaluating the safety and effectiveness of tebentafusp in previously treated patients with advanced uveal melanoma

Posted by on Oct 25, 2022 in Melanoma | 0 comments

In a nutshell The study evaluated the safety and effectiveness of tebentafusp (Kimmtrak) in patients with metastatic uveal melanoma who had received previous treatments. The study found that tebentafusp had promising effectiveness and a good safety profile in these patients. Some background Uveal melanoma is a rare and aggressive eye tumor....

Read More

Evaluating the effectiveness and safety of capecitabine maintenance versus active monitoring for the treatment of patients with metastatic colorectal cancer.

Evaluating the effectiveness and safety of capecitabine maintenance versus active monitoring for the treatment of patients with metastatic colorectal cancer.

Posted by on Oct 24, 2021 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of capecitabine (Xeloda) as maintenance therapy versus active monitoring for the treatment of patients with stable metastatic colorectal cancer (mCRC). The data showed that capecitabine maintenance improved survival without cancer worsening with manageable side effects for these...

Read More

Evaluating long-term outcomes of autologous SCT for patients with recurrent multiple myeloma

Evaluating long-term outcomes of autologous SCT for patients with recurrent multiple myeloma

Posted by on Aug 7, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the outcomes of autologous stem cell transplantation (ASCT) for patients with recurrent multiple myeloma (MM). This study found that long-term outcomes for these patients were promising, especially for patients who had the transplant right away after a first relapse. Some background Multiple myeloma (MM) is a type of...

Read More

Adding daratumumab to pomalidomide and dexamethasone therapy for treatment of relapsed/refractory multiple myeloma.

Adding daratumumab to pomalidomide and dexamethasone therapy for treatment of relapsed/refractory multiple myeloma.

Posted by on Jul 17, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of adding daratumumab (Darzalex) to pomalidomide (Pomalyst) and dexamethasone (Decadron) therapy for patients with previously treated relapsed or refractory (r/r) multiple myeloma (MM). The data showed that adding daratumumab to pomalidomide and dexamethasone regimen reduced the risk of...

Read More

Evaluating loncastuximab tesirine for patients with recurrent or hard-to-treat DLBCL

Evaluating loncastuximab tesirine for patients with recurrent or hard-to-treat DLBCL

Posted by on Jul 11, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of loncastuximab tesirine (Zynlonta) for patients with diffuse large B-cell lymphoma (DLBCL) that returned or stopped responding to treatment. This study concluded that this treatment was safe and effective for these patients. Some background DLBCL is one of the most common types of...

Read More

Evaluating CAR T-cell therapy before stem cell transplantation for patients with B-cell ALL

Evaluating CAR T-cell therapy before stem cell transplantation for patients with B-cell ALL

Posted by on Jul 11, 2021 in Leukemia | 0 comments

In a nutshell This study evaluated the safety and effectiveness of CAR T-cell therapy versus chemotherapy before a stem cell transplant (SCT) for patients with recurrent or non-responsive B-cell acute lymphoblastic lymphoma (B-ALL). The authors concluded that CAR T-cell therapy followed by SCT was safe and effective for these patients. Some background...

Read More

How effective is umbralisib as treatment for patients with relapsed or refractory low-grade lymphoma?

How effective is umbralisib as treatment for patients with relapsed or refractory low-grade lymphoma?

Posted by on Apr 11, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The authors assessed the safety and effectiveness of umbralisib (Ukoniq) in patients with relapsed or refractory (r/r) indolent (low-grade) non-Hodgkin lymphoma (iNHL).   The study concluded that umbralisib was well tolerated and effective for patients with r/r iNHL. Some background iNHL is a slow-growing cancer of...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2024 Medivizor